Drug Profile
Research programme: interleukin-6 inhibitors - Y's Therapeutics
Alternative Names: Anfil6; YSIL-6; YSIL6-O-RA; YSIL6-T-PSLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Ys Therapeutics
- Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Small molecules
- Mechanism of Action Interleukin 6 inhibitors; Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Rheumatoid arthritis
- Discontinued Crohn's disease; Psoriasis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Rheumatoid-arthritis in Japan (PO)
- 28 Feb 2011 Early research is ongoing in Japan
- 28 Jul 2004 Discontinued - Preclinical for Crohn's disease in Japan (PO)